Starton logo-pantone2112C.jpg
Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application Protecting Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents
October 04, 2021 07:00 ET | Starton Therapeutics, Inc.
PARAMUS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, today...
AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
September 22, 2021 12:09 ET | AB Science
PRESS RELEASE AB SCIENCE RECEIVES HEALTH CANADA APPROVAL LETTER TO COMMENCE PHASE I/II TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AB8939 IS A NEW GENERATION SYNTHETIC...
AB Science a reçu l’approbation de l’autorité de santé canadienne pour initier une étude de Phase I/II avec sa molécule AB8939 dans le traitement de la leucémie myéloïde aiguë (LMA)
September 22, 2021 12:09 ET | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE L’AUTORITE DE SANTÉ CANADIENNE POUR INITIER UNE ÉTUDE DE PHASE I/II AVEC SA MOLÉCULE AB8939 DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË...
20170406 Telix Logo.png
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
August 16, 2021 19:55 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LONDON , Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the London-based Great Ormond Street Hospital...
22157.jpg
Global Chronic Lymphocytic Leukemia (CLL) Disorder Clinical Market Report 2021-2027
July 06, 2021 08:08 ET | Research and Markets
Dublin, July 06, 2021 (GLOBE NEWSWIRE) -- The "Chronic Lymphocytic Leukemia (CLL)" report has been added to ResearchAndMarkets.com's offering. Chronic lymphocytic leukemia (CLL) is a disorder where...
logo.gif
Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
June 21, 2021 08:30 ET | Auris Medical AG
Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive body of...
22157.jpg
Global Acute Lymphoblastic Leukemia (ALL) Clinical Landscape Market Report 2021 - Novartis has the Highest Number of Completed Clinical Trials with 47
June 18, 2021 05:28 ET | Research and Markets
Dublin, June 18, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Acute Lymphoblastic Leukemia (ALL)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers...
NEW LEADING-EDGE TREATMENT FOR LEUKEMIA NOW OFFERED AT NICKLAUS CHILDREN'S HOSPITAL
June 10, 2021 09:54 ET | Nicklaus Children's Hospital
MIAMI, June 10, 2021 (GLOBE NEWSWIRE) -- Nicklaus Children's Hospital is one of only a few pediatric hospitals in Florida, and the only one in South Florida, to offer the latest immune cell...
22157.jpg
Worldwide Multiple Myeloma Treatment Industry to 2029 - Players Include Janssen Biotech, Bristol-Myers Squibb and Novartis Among Others
May 13, 2021 05:03 ET | Research and Markets
Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and...
PRPO logo.png
Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time
May 10, 2021 10:30 ET | Precipio, Inc.
NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has launched a new, four-hour Acute Myeloid Leukemia (AML)...